Results 131 to 140 of about 402,477 (353)

Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions.
Philipp Klyscz   +8 more
wiley   +1 more source

Modeling Survival Analysis in Gastric Cancer Patients Using the Proportional Hazards Model of Cox

open access: yesمجله اپیدمیولوژی ایران, 2007
Background & Objectives: Cancer has been traditionally regarded as a fatal disease; it is a major public health problem in many countries throughout the world.
B Moghimi Dehkordi   +5 more
doaj  

An Application of the Cox-Aalen Model for Breast Cancer Survival

open access: yesAustrian Journal of Statistics, 2016
Semiparametric hazard function regression models are among the well studied risk models in survival analysis. The Cox proportional hazards model has been a popular choice in modelling data from epidemiological settings.
Ileana Baldi   +5 more
doaj   +1 more source

Association of Higher Levels of High‐Sensitivity C‐Reactive Protein With Future Development of Psoriatic Arthritis in Psoriasis: A Prospective Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to assess whether high‐sensitivity C‐reactive protein (hsCRP) levels could predict the development of psoriatic arthritis (PsA) in patients with psoriasis. Methods We analyzed data from a prospective cohort of patients with psoriasis without PsA at enrollment.
Lihi Eder   +5 more
wiley   +1 more source

Time Trends and Predictors of Gout Remission Over 6 Years

open access: yesArthritis Care &Research, EarlyView.
Objective This study aims to describe the trends in remission rates over 6 years of follow‐up among people with gout taking urate‐lowering therapy (ULT) and to identify variables that predict remission. Methods A post hoc analysis was conducted using data from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial ...
Adwoa Dansoa Tabi‐Amponsah   +5 more
wiley   +1 more source

The Cox Proportional Hazards Model in the Analysis of Property Transactions [PDF]

open access: yesFolia Oeconomica Stetinensia, 2009
The Cox Proportional Hazards Model in the Analysis of Property TransactionsThe main aim of the paper is to present the methodological basis of housing transactions which uses duration analysis and Cox' proportional hazards model. The study will take into consideration single episodes with one starting point (the purchase of a flat on the resale market)
openaire   +2 more sources

Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis

open access: yesArthritis Care &Research, Accepted Article.
Background Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our
Shivani Garg   +9 more
wiley   +1 more source

Heterogeneity of Rheumatoid Arthritis‐Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations with Disease Outcomes

open access: yesArthritis Care &Research, Accepted Article.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999‐2021. RA‐ILD patients were
Bryant R. England   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy